Faulty List At SAIHST, we have faculties from various backgrounds such as ; basic science, clinical medicine, pharmacology, engineering, business etc. SAIHST is always open for future competent faculties to lead biomedical science.
| Jong Wook Chang / Ph.D. |
Name : Jong Wook Chang Ph.D.
Department : SAIHST
Title : Professor
Campus : 삼성서울병원 캠퍼스
Office : 삼성서울병원 미래의학관 지하3층
E-mail : changjw@skku.edu, jongwook.chang@samsung.com
Homepage : https://www.cgtlabskku.com/
Lab. title : Lab of Cell and Gene Therapy
Related Department : 융합의과학과, 의료기기산업학과, 임상연구설계평가학과
Print
PDF Download
|
|
■Careers
1999-2005 Ph.D. GIST 2005-2007 Postdoctoral Researcher, KIST Former Research Director, MEDIPOST Co., Ltd. Present GMP Director & Professor, Samsung Medical Center Present 24’ Industry-Academic Cooperation Committee Chair Korean Society for Stem Cell Research Present ENCell. Co. ltd CEO (https://encellinc.com/main/) Present International Journal of Stem Cells, Associate Editor Present Professor, Sungkyunkwan University, SAIHST ■ Lap Introduction Our lab has been focused on developing advanced cell & gene therapy products as well as GMP manufacturing platforms. We are specifically focused on culturing mesenchymal stem cells (MSCs) isolated from human Wharton’s jelly and/or placenta as a therapeutic candidate to treat nervous and neuromuscular diseases. It is widely accepted among the scientific community that MSCs exert therapeutic effects by secreting various proteins to the lesion site. Such biological properties and therapeutic mechanisms of MSCs have laid the foundation to initiate the commercialization of cell therapy. One of our major objectives is to investigate the mechanisms involved in the therapeutic properties of MSCs specifically in relation to neuromuscular diseases which will play a fundamental role in the development of next-generation cell-therapies. We have a wide range of interests spanning from stem cell therapy, anticancer immunotherapy, gene therapy, and development of advanced cell & gene therapy products for the treatment of incurable diseases. Current and advanced cell / gene therapy products must adhere to GMP standards. Thus, it is imperative to develop novel technologies required for the manufacture and quality control of these products. It is also of utmost importance to continually support the training of GMP professionals. Keywords: Advanced Regenerative Medicine and Advanced Biological Products, Stem cell therapy, Gene therapy, Neuromuscular diseases, GMP ■ Selected Publications (2019 ~ Present) 1. Wharton’s Jelly-Derived Mesenchymal Stem Cells with High Aurora Kinase A Expression Show Improved Proliferation, Migration, and Therapeutic Potential. Stem Cells Int. 2022 Apr 11;2022:4711499 2. Exposure of Mesenchymal Stem Cells to an Alzheimer's Disease Environment Enhances Therapeutic Effects. Stem Cells Int. 2021 Mar 16;2021:6660186. 3. Fibulin 5, a human Wharton's jelly‐derived mesenchymal stem cells‐secreted paracrine factor, attenuates peripheral nervous system myelination defects through the Integrin‐RAC1 signaling axis. Stem Cells. 2020 Oct 27;38(12):1578-1593 4. Comparative Proteomic Analysis of the Mesenchymal Stem Cells Secretome from Adipose, Bone Marrow, Placenta and Wharton's Jelly. Int J Mol Sci. 2021 Jan 15;22(2):845. 5. Cerebrospinal fluid from Alzheimer's disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer's disease. Sci Rep. 2019 Jan 24;9(1):564. +69 Additional papers |